Drug maker Wockhardt has received tentative approval from the US health regulator to market Olopatadine hydrochloride eye drops in the American market. The company has received approval from the US Food and Drug Administration (USFDA) to market 0.1% solution of Olopatadine hydrochloride eye drops, used in treating allergic conjunctivitis. Olopatadine hydrochloride eye drops are the generic equivalent of Alcon Laboratories Inc's Patanol brand.The patent covering this product is under litigation in the US courts and Wockhardt will launch the product after resolution of the same. According to IMS Health data, the total market for Olopatadine in the US is nearly $230 million. Wockhardt is only one of the three companies to receive a tentative approval for this product till date. crackcrack
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1279.70 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2245.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: